All issues
Predecessor
Volume 33, Issue 4
Displaying 1-18 of 18 articles from this issue
- |<
- <
- 1
- >
- >|
-
SONOSUKE DOI, AKIRA FUJIMOTO, MASANAO ITO, OSAMU SUGIMOTO, KIYOSHIGE T ...1980 Volume 33 Issue 4 Pages 411-415
Published: April 25, 1980
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESSTen patients suffering from genital organ infections, urinary tract infections and symptomless bacteriuria were treated with cefamandole (CMD).CMD was administered intravenously and drip infusion at a dosage of4.0g/day for4-10days.
Clinical results obtained were as follows: Of6patients with genital organ infections, excellent responses were seen in 2 patients, good responses in 4 patients.Of 3 patients with urinary tract infections, excellent responses were seen in2patients, and good response in1patient.The overall efficacy rate was100%.In the cases of urinary tract infections and symptomless bacteriuria, 3strains of E.coli and1strain of Streptococcus faecalis disappeared. On the other hand, in genital organ infections, we had no bacterial findings.
No significant reaction was observed in clinical laboratory findings of hemogram or in test on renal and hepatic functions, except slight transient leukopenia observed in1patient.View full abstractDownload PDF (687K) -
KOJI HIRABAYASHI, ETSUKO OKADA1980 Volume 33 Issue 4 Pages 416-426
Published: April 25, 1980
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS1) Tissue concentrations of cefamandole (CMD) one hour after the end of2g/30-60minutes drip infusion were7.3-13μg/g in uterus, ovary and oviduct.These concentrations were higher than MICs of 70-100% of causative organisms, including Staphylococcus aureus, Escherichia coli, Proteus mirabilis, Enterobacter and Citrobacter, isolated from the infections in the field of obstetrics and gynecology.
2) CMD was administered to14patients with moderate infections in the field of obstetrics and gynecology at a daily dose of 4 g for 5-7 days. The overall clinical efficacy obtained was as follows; excellent in7cases (50%), good in3cases (21%) and poor in4cases (29%).
3) Antimicrobial activity of CMD against causative organisms resembled that of CEZ.
4) No adverse effects and abnormal laboratory findings were observed.
From the above, we considered that CMD was an effective and safe antibiotic against infections in the field of obstetrics and gynecology.View full abstractDownload PDF (1215K) -
FUMIO YAMADA1980 Volume 33 Issue 4 Pages 427-428
Published: April 25, 1980
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESSCefamandole, a new antibiotic with various characteristics was applied clinically in the field of obstetrics and gynecology, and following results were obtained.
Cefamandole was administered to 8 cases with cystit is, 2 cases with pelvic infection. The organisms isolated were 5 cases of Escherichia coli, 4 cases of Staphylococcus epidermidis and one case of Klebsiella.
Bacteria disappeared in all cases after 5-day treatment with cefamandole. No side effec t s of the drug were noticed throughout all cases.
From the above mentioned clin ical experience, cefamandole is considered to be a useful drug for clinical application.View full abstractDownload PDF (300K) -
MASAHIKO KAWAMURA, KIMIEKO UOZUMI, TAKAKO MAKI, NOBUO TAUCHI, YOSHIKI ...1980 Volume 33 Issue 4 Pages 429-432
Published: April 25, 1980
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESSFive patients with suppurative tonsillitis (1), urinary tract infection (1), staphylococcal impetigo (1), cervical lymphadenitis (1) and mycoplasma pneumonia were treated with cefamandole (CMD). CMD was administered by one shot intravenous or drip infusion at a dosage of 100-135 mg/kg/day for 4-14 days.
Of 5 patients with those infections, excellent response was obtained in 3 patients, good response in 1 patient and unknown response in 1 patient. The overall efficacy rate was 100% except unknown response in mycoplasma pneumonia.
In 3 of these y 5 cases causative organisms were S. epidermidis, E.coli, and S.aureus, respectively.
These organisms were all eliminated. No side effects were observed.View full abstractDownload PDF (781K) -
OSAMU KOBAYASHI1980 Volume 33 Issue 4 Pages 433-435
Published: April 25, 1980
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
KENTARO OHMORI, MASATAKA SHIRAI, TOSHIO KIYOSAKI, SENJI HORI, HIROSHI ...1980 Volume 33 Issue 4 Pages 436-452
Published: April 25, 1980
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESSJapan White rabbits were treated with aclacinomycin A, a new anthracycline antitumor antibiotic, at a dose of 6.25 or 25.0 mg/kg by single intravenous, or 12.5 or 50.0 mg/kg by single oral administration, respectively. Beagle dogs were treated at a dose of 3.0 or 6.0 mg/kg by singleintravenous injection. In rabbits in higher dose groups, RBC and WBC counts as well as lymphocyte ratio in peripheral blood decreased on day 1. Nucleated cell counts and erythroid elements in bone marrow decreasedt.o raise M/E ratio (Myeloid/Erythroidr atio) on day 3. In a dog given at 6.0 mg/kg, WBC and platelet counts, lymphocyte and neutrocyte per cents in peripheral blood and also nucleated cells. particularly erythroid elements in bone marrow remarkably decreased on day 3 accompanied with an increase in M/E ratio. These changes were almost completely recovered by day 14 in both animals. No abnormalities were found in lower dose groups. Male Wistar rats, treated with the drugat a dose of 1.5 mg/kg by daily intraperitoneal injection for 30 days, showed slight decreases in peripheral WBC and RBC counts and M/E ratio in bone marrow. No change was observed in rats treated at 0, 75mg/kg and less for 30 days.View full abstractDownload PDF (8409K) -
KENTARO OHMORI, SHINICHI HIRANO, TOSHIO KIYOSAKI, SENJI HORI, HIROSHI ...1980 Volume 33 Issue 4 Pages 453-465
Published: April 25, 1980
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESSAclacinomycin A, a new anthracycline antitumor antibiotic, was given to rabbits by single instillation or single intracutaneous injection and to guinea pigs by single subcutaneous or intramuscular injection to examine the irritative effect.
Slight dilatation of blood vessel and swelling in the conjunctiva and nictitating membrane were observed in the eyes of rabbits given 1% solution.Edema in the bulbar conjunctiva, iris and cornea was histologically noted.Washing of the eyes after drug instillation prevented these damages.Subcutaneous and intracutaneous injections of 1% solution (0.2 ml) gave hyperemia, swelling and necrosis at injection site.Cellular infiltration, fibrosis and necrosis were histologically detected.
Intramuscular injection of1% solution (0.2ml) also provided induration and swelling at injection site.Histologically cellular infiltration and necrosis were observed. These irritative effects were much slighter in administration of 0.1%solutiom. No change was observed with 0.01% solution.View full abstractDownload PDF (17162K) -
I.STABILITY OF SOLUTION OF ACLACINOMYCIN HYDROCHLORIDESHUNRO MORI, NAOBUMI SHINDO, HIROSHI MIURA, TOSHIKAZU OKI, TAIJI INUI1980 Volume 33 Issue 4 Pages 466-471
Published: April 25, 1980
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESSAclacinomycin is an antitumor anthracycline antibiotic isolated from the culture broth of Streptomyces galilaeus MA144-M1.In this study, the effects of heat, light and pH on the aqueous solution of aclacinomycin hydrochloride (ACM-HC1) were investigated.The following, results were found:
(1) The kinetic studies revealed that the thermal inactivation of ACM-HC1 solution (pH 4.5) was based on the apparent first-order reaction and that ARRHENIUS equation was confirmed to be established between the rate constants and temperatures.When ACM-HC1 solution was stored at 20, 10 and 5°C, the estimated term of ACM-HC1 solution at the time when the initial activity (100%) reduced to 90% residual concentration was 1.5, 6 and 12 months, respectively.
(2) It was clarified by pH-log k profile that ACM-HC1 solution was most stable near at pH 4.5.
(3) The higher the buffer concentration was used, the faster the degradation rate, but there was no difference between the residual activity ratios at the various concentrations of ACM-HC1 solution.
(4) The inactivation of ACM-HC1 solution under sunlight occurred in a type of zero-order reaction so that the faster inactivation rates were obtained at the more diluted concentrations of ACMHCI.
(5) The major degradation products of ACM-HC1 solution were 1-deoxypyrromycin (DP), MA144 Si (Si) and bisanhydroaklavinone (F1).DP and S1 were mainly found at pH below4.0and Fl at pH above5.0.The degradation under sunlight gave Ll (N-monodemethyl ACM) accompanied by the degradation of aglycone moiety in part.View full abstractDownload PDF (787K) -
MASARU YOSHIDA, YORIYUKI NONOSHITA, SHINGI SAITO, UHYONG HYON, TERUJI ...1980 Volume 33 Issue 4 Pages 472-477
Published: April 25, 1980
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESSThe antibiotic activity of sulbenicillin and cefacetrile was determined after storage at 20° for up to 7 days in human gall-bladder and common duct bile.In gall-bladder bile, both drugs could not retain their initial activity after 3days.The decay curves in antibiotic activity in the ductal bile revealed large variations, as given in Figs.5and6.The 7th day activity of both drugs decreased with the rise in initial pH level of bile.Significant correlation was noted between bile acid concentration in bile and cefacetrile activity on the7th day.View full abstractDownload PDF (730K) -
V.Fertility study in ratsKIYONORI TAUCHI, HIROAKI KAWANISHI, NORIYUKI IGARASHI, YASUYUKI MAEDA, ...1980 Volume 33 Issue 4 Pages 478-486
Published: April 25, 1980
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
VI.Teratogenic study in ratsKIYONORI TAUCHI, HIROAKI KAWANISHI, NORIYUKI IGARASHI, YASUYUKI MAEDA, ...1980 Volume 33 Issue 4 Pages 487-496
Published: April 25, 1980
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
VII.Teratogenic study in rabbitsKIYONORI TAUCHI, HIROAKI KAWANISHI, NORIYUKI IGARASHI, YASUYUKI MAEDA, ...1980 Volume 33 Issue 4 Pages 497-502
Published: April 25, 1980
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
VIII.Peri-and post-natal development study in ratsKIYONORI TAUCHI, HIROAKI KAWANISHI, NORIYUKI IGARASHI, YASUYUKI MAEDA, ...1980 Volume 33 Issue 4 Pages 503-509
Published: April 25, 1980
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
SHOICHI ONODERA, YUKIHIKO OISHI, TOYOHEI MACHIDA1980 Volume 33 Issue 4 Pages 510-513
Published: April 25, 1980
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
TAKEFUMI MORIHANA, KAZUMASA UEDA, MARIKO MURAOKA, TETSUYA TSUSHIMA, MU ...1980 Volume 33 Issue 4 Pages 514-521
Published: April 25, 1980
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
HIDEKI YOSHIDA, YOSHIO HIGAKI, HAJIME OGAWA, HIROSHI IGUCHI, MASANOBU ...1980 Volume 33 Issue 4 Pages 522-525
Published: April 25, 1980
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS -
NOBUO KAWAMURA, KEISHI OKADA, MASAAKI OHKOSHI, MASAYOSHI TSUCHIDA, SHI ...1980 Volume 33 Issue 4 Pages 526-538
Published: April 25, 1980
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESSClinical trials with KW-1062, a new aminoglycoside antibiotic, were carried out on the basis of the pre-clinical studies.
Absorption and excretion of KW-1062 were studied in the healthy adults after single and multiple intramuscular administration. The blood concentration at single administration of 120 and 180mg of KW-1062 reached the peak of 7 and 12μ/ml respectively 30 minutes after administration.The half life was constantly about 2 hours. The 10-hour urinary recovery rate was 55.6% and 60.8% at each of the above doses.No accumulation of KW-1062 in plasma was observed with multiple administration of 180 mg twice a day for 5 days.No adverse reactions (on blood, renal function and hearing) were observed.From these results, the dose of 360mg/day proved to be as safe as that of 240mg/day.
KW-1062 was administered to 155 patients at daily dose of 240mg and 360mg for 1-11 days. The cases collected and analyzed consisted of 105 patients with complicated U.T.I., 10 with acute and uncomplicated pyelonephritis, 16 with infection of neurogenic bladder after spinal cord injury and others.Of 105 patients with complicated U.T.I., 65 were administered KW-1062 at 360 mg daily, and 40 at 240mg.KW-1062 was found to be effective in 52.5% of the 240mg/day group, in 40% of the 360mg/day group of complicated U.T.I., when evaluated on the basis of the criteria by the U.T.I.study group, and in 90% of patients with acute and uncomplicated pyelonephritis.
Of 155 patients subjected to KW-1062 treatment, only one experienced tinnitus and nausea, and 17 had abnormal values in their laboratory findings.View full abstractDownload PDF (1367K) -
YOSHIRO SAWAE, MASAHIDE TAKII1980 Volume 33 Issue 4 Pages 539-548
Published: April 25, 1980
Released on J-STAGE: May 17, 2013
JOURNAL FREE ACCESS
- |<
- <
- 1
- >
- >|